mechanism of glp 1 receptor agonists GLP-1 for individualized treatment type 2 diabetes mellitus Frontiers | Mechanisms of action

Liraglutide suppresses TNF- and monocyte chemoattractant protein-1 (MCP-1) expression in monocytes derived from healthy participants

Accumulating evidence demonstrates that GLP-1RAs exert heterogeneous effects across different tumor types (Table 1)

Reducing ischemia-reperfusion injury, increasing brain healing, limiting inflammatory response, and oxidative stress are all ways in which GLP-1R activation can lessen the extent of cerebral infarction [131], [132], [133], [134]

Basics of meta-analysis: I2 is not an absolute measure of heterogeneity

Several uncertainties remain

The incretin-related therapies dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) not only improve glycaemic control with a low risk of hypoglycaemia but can also have beneficial non-glycaemic effects such as avoidance of weight gain, reduced blood pressure and improvements in beta-cell function and cardiovascular risk biomarkers 1 3